Thomas Gad - 17 Jan 2025 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
CHIEF BUSINESS OFFICER, Director
Signature
/s/ John LaRocca, Attorney-in-Fact
Issuer symbol
YMAB
Transactions as of
17 Jan 2025
Transactions value $
$0
Form type
4
Filing time
22 Jan 2025, 19:04:08 UTC
Previous filing
20 Sep 2024
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +32K +17.63% $0.00 214K 17 Jan 2025 Direct F1
holding YMAB Common Stock 67.7K 17 Jan 2025 By GAD Enterprises LLC F2
holding YMAB Common Stock 60K 17 Jan 2025 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +64K $0.00 64K 17 Jan 2025 Common Stock 64K $6.16 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2026, January 17, 2027 and January 17, 2028, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
F4 Represents stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.
F5 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2026, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.